NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.